Eyepoint Pharmaceuticals Inc (EYPT) Short Interest Update

Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) was the target of a significant growth in short interest in October. As of October 31st, there was short interest totalling 2,723,912 shares, a growth of 45.6% from the October 15th total of 1,871,370 shares. Based on an average daily volume of 832,548 shares, the days-to-cover ratio is currently 3.3 days. Approximately 6.5% of the shares of the stock are sold short.

Institutional investors have recently added to or reduced their stakes in the company. Bard Associates Inc. bought a new stake in shares of Eyepoint Pharmaceuticals during the second quarter valued at approximately $189,000. Essex Investment Management Co. LLC raised its position in shares of Eyepoint Pharmaceuticals by 65.0% during the third quarter. Essex Investment Management Co. LLC now owns 134,509 shares of the company’s stock valued at $480,000 after buying an additional 52,977 shares during the last quarter. FineMark National Bank & Trust bought a new stake in shares of Eyepoint Pharmaceuticals during the second quarter valued at approximately $118,000. Creative Planning bought a new stake in shares of Eyepoint Pharmaceuticals during the second quarter valued at approximately $162,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Eyepoint Pharmaceuticals during the second quarter valued at approximately $2,339,000. Hedge funds and other institutional investors own 62.85% of the company’s stock.

Shares of NASDAQ:EYPT opened at $2.30 on Friday. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 1.48. Eyepoint Pharmaceuticals has a 1-year low of $0.93 and a 1-year high of $3.94. The company has a market cap of $172.87 million, a price-to-earnings ratio of -3.97 and a beta of 1.73.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings data on Tuesday, November 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The company had revenue of $0.49 million for the quarter, compared to the consensus estimate of $0.70 million. Eyepoint Pharmaceuticals had a negative net margin of 2,622.93% and a negative return on equity of 377.64%. On average, equities research analysts predict that Eyepoint Pharmaceuticals will post -0.42 EPS for the current fiscal year.

Several brokerages have weighed in on EYPT. Zacks Investment Research raised shares of Eyepoint Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 28th. ValuEngine raised shares of Eyepoint Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, October 29th. HC Wainwright set a $3.00 price target on shares of Eyepoint Pharmaceuticals and gave the company a “buy” rating in a report on Friday, July 27th. Finally, B. Riley lifted their price target on shares of Eyepoint Pharmaceuticals from $5.00 to $6.00 and gave the company a “buy” rating in a report on Tuesday, October 16th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Eyepoint Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $5.50.

ILLEGAL ACTIVITY WARNING: This article was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://sportsperspectives.com/2018/11/10/eyepoint-pharmaceuticals-inc-eypt-short-interest-update.html.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials.

Further Reading: Earnings Per Share

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply